Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

BACKGROUND: Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 signalling. The aim of this study was to compare the effects of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Res Ther
Autors principals: Gabay, Cem, Burmester, Gerd R., Strand, Vibeke, Msihid, Jérôme, Zilberstein, Moshe, Kimura, Toshio, van Hoogstraten, Hubert, Boklage, Susan H., Sadeh, Jonathan, Graham, Neil M. H., Boyapati, Anita
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7137491/
https://ncbi.nlm.nih.gov/pubmed/32264972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02163-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars